Gastric Cancer Gene Expression Profile Signature And Biomarkers Identification

Gastric cancer is one of the most common malignancies in digestivesystem in the world. Early diagnosis and accurate staging are the basementfor improving the effect of gastric cancer treatment.This research used Affymetrix Human U133Plus2.0microarray toobtain gene expression profiles of115tumor tissues from gastric cancerpatients and20normal gastric mucosa, investigate differentially expressedgenes between gastric cancer and normal mucosa. Base on the geneexpression profiles and pathological data, we also constructed aco-expression network for gastric cancer. Further network analysis showedseveral biomarkers including MAP3K7, MAP3K2, NF1, ARRB2, MET,PAK2, TPR, E2F3, SOS1, ATF2, PARVB, DAPK3, EPAS1, EP300, STK4,ACVR1C, FZD8, CTNNB1, PTPRR and MAP3K13, which mainly enrichedin the MAPK pathway, could be used to separate the primary tumor samplesfrom the normal gastric mucosa samples. And another group of biomarkersincluding ILK, HSPG2, FYN, CAV1, TNC, ZAK, MYLK, FLNA, MYL9and MMP2, whose biological functions were concentrated in regulating theprotein kinase activities, could distinguish the early carcinoma samples fromthe advanced carcinoma samples. We also identified several biomarkersimproving TNM staging including JAKMIP3, MAGI2, SYNE1, DCX,CLUL1, ZNF578, MYOZ2and PGR, were in inverse proportion to the five-year survival rate of gastric cancer patients. In addition, genes involvedin Focal Adhesion pathway induced carcinogenesis and progression of gastriccancer.The findings in the current study could reveal an in-depth understandingof the mechanism of carcinogenesis of gastric cancer, providing usefulinformation for screening biomarkers for both early diagnosis and prognosisof patients.